Diamond Infraco 1 Pty Ltd, the bidding vehicle for IFM Global Infrastructure Fund, has confirmed satisfaction of two major regulatory conditions in its takeover of Atlas Arteria Limited. The European Union merger control approval and US Hart-Scott-Rodino clearance have now been obtained, representing critical milestones that remove significant execution risk from the proposed acquisition.
The Second Supplementary Bidder’s Statement, released on 26 May 2026, updates shareholders on the regulatory pathway following the initial bidder’s statement lodged on 27 April and the first supplementary statement from 20 May. The progression of regulatory approvals through multiple jurisdictions demonstrates the cross-border complexity of acquiring a major Australian infrastructure asset with international operations. The satisfaction of both EU and US conditions clears the way for remaining approval hurdles, though the statement does not provide detail on other potential conditions that may still be outstanding.
The bidder has also formally registered its strong disagreement with the independent directors of Atlas Arteria, who released their own Target’s Statement on the same day recommending shareholders reject the offer. This divergence signals an active takeover contest where the board and bidder are presenting competing views on the merits of the transaction. The bidder indicated it would provide detailed responses to the Target’s Statement in due course, suggesting further correspondence between the parties is forthcoming and shareholders should expect detailed arguments from both sides in coming weeks.
For Atlas Arteria shareholders, the regulatory progress is material. The removal of major regulatory conditions typically signals momentum toward deal completion, though it also makes the board’s rejection recommendation noteworthy. Shareholders must assess whether the independent directors’ reasons for rejection outweigh the bidder’s confidence in proceeding. The fact that a sophisticated infrastructure fund backed by IFM is willing to proceed after securing these regulatory approvals suggests sufficient confidence in the transaction structure and valuation.
Investors should monitor several developments in coming weeks. The detailed response from the bidder to the Target’s Statement may contain additional information about deal terms, financing arrangements, or synergy expectations. Any further regulatory approvals or conditions being satisfied will be positive indicators for deal momentum. Equally important is the shareholder voting outcome, which will ultimately determine whether the takeover succeeds. The extended supplementary statement regime suggests this is a complex transaction where information disclosure continues to evolve as conditions are met and positions are clarified.
Our exclusive top 5 stock picks
Five high conviction stocks that didn't make the public list. Backed by institutional research. Subscribe for free access.
Thanks for subscribing, please check your email to confirm your subscription to instantly access your report.
The announcement is price sensitive and has been classified as material by the ASX, reflecting the significance of regulatory clearance and the ongoing takeover contest for shareholders considering their investment position.
View the full ASX announcement (PDF)
About Atlas Arteria Limited (ASX: ALX)
Atlas Arteria Limited is a global owner, operator, and developer of toll roads with a portfolio spanning France, Germany, and the United States. The company holds significant interests in major toll road networks including approximately 31% of the APRR motorway network in eastern France, the Warnow Tunnel in Germany, the Chicago Skyway in the United States, and full ownership of the Dulles Greenway in Virginia. The company is based in Melbourne, Australia and operates toll road businesses that generate revenue from motorway usage across multiple countries.
If you would like to discuss this announcement, request a callback or call us on 1300 889 603.